Online inquiry

IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9044MR)

This product GTTS-WQ9044MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets FLT1 gene. The antibody can be applied in Colon Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001159920.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2321
UniProt ID P17948
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ9044MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12089MR IVTScrip™ mRNA-Anti-CD38, MOR-03087(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-03087
GTTS-WQ11128MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ12043MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ609MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ4092MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BI-204
GTTS-WQ1889MR IVTScrip™ mRNA-Anti-PDCD1, AGEN2034(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGEN2034
GTTS-WQ7779MR IVTScrip™ mRNA-Anti-MMP9, GS-5745(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GS-5745
GTTS-WQ7200MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-8A-F9Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-8A-F9Z CAR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW